Technical Analysis for ONC - Oncolytics Biotech Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.435 | 1.41% | 0.020 |
Earnings due: Aug 12
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 1.41% | |
| Bollinger Band Squeeze | Range Contraction | 1.41% | |
| Fell Below 20 DMA | Bearish | 1.77% | |
| Bollinger Band Squeeze | Range Contraction | 1.77% | |
| Narrow Range Bar | Range Contraction | 1.77% | |
| Doji - Bullish? | Reversal | 1.77% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 5 hours ago |
| 10 DMA Support | about 5 hours ago |
| 50 DMA Resistance | about 9 hours ago |
| 10 DMA Resistance | about 9 hours ago |
| Gapped Up (Full) | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 2024-08-12
Oncolytics Biotech Inc. Description
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Clinic Cancer RTT Therapy Clinical Trial Oncology Lung Cancer Blastoma Chemotherapy Non Small Cell Lung Cancer Glioblastoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.48 |
| 52 Week Low | 1.2 |
| Average Volume | 26,477 |
| 200-Day Moving Average | 1.639 |
| 50-Day Moving Average | 1.430 |
| 20-Day Moving Average | 1.415 |
| 10-Day Moving Average | 1.431 |
| Average True Range | 0.041 |
| RSI (14) | 53.05 |
| ADX | 9.13 |
| +DI | 22.902 |
| -DI | 18.001 |
| Chandelier Exit (Long, 3 ATRs) | 1.378 |
| Chandelier Exit (Short, 3 ATRs) | 1.462 |
| Upper Bollinger Bands | 1.477 |
| Lower Bollinger Band | 1.352 |
| Percent B (%b) | 0.66 |
| BandWidth | 8.865 |
| MACD Line | 0.000 |
| MACD Signal Line | -0.002 |
| MACD Histogram | 0.0022 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.480 | ||||
| Resistance 3 (R3) | 1.480 | 1.465 | 1.473 | ||
| Resistance 2 (R2) | 1.465 | 1.454 | 1.465 | 1.470 | |
| Resistance 1 (R1) | 1.450 | 1.446 | 1.443 | 1.450 | 1.467 |
| Pivot Point | 1.435 | 1.435 | 1.431 | 1.435 | 1.435 |
| Support 1 (S1) | 1.420 | 1.424 | 1.413 | 1.420 | 1.403 |
| Support 2 (S2) | 1.405 | 1.416 | 1.405 | 1.400 | |
| Support 3 (S3) | 1.390 | 1.405 | 1.398 | ||
| Support 4 (S4) | 1.390 |
